This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

Xofigo

^®
▼ (radium-223 dichloride)

Patient identification & Treatment sequencing

mCRPC patients with symptomatic bone metastases should be treated early with Xofigo (prior to visceral metastases)

Introduce Xofigo for your mCRPC patients who have progressed on two lines of systemic therapy (other than LHRH analogues) or if ineligible for systemic therapy.

Identifying the right patients for treatment with Xofigo

Inclusion criteria for Xofigo following 2 prior lines or ineligible for systemic therapy:

^{Xofigo is not recommended in patients with a low level of osteoblastic bone metastases.}

How Xofigo may fit in to your treatment sequence:

^{These are illustrative algorithms based on the revised EU indication for Xofigo. Not all potential treatment options are shown. Concurrent use of bone health agents to treat osteoporosis or for patients with bone metastases is recommended. Sequential use of abiraterone and enzalutamide (or vice versa) is not considered as an option due to likely futility of treatment. Consider clinical trials or best supportive care after all available systemic therapies have been administered.}

Use Xofigo while there is an opportunity for action before the development of visceral metastases

Xofigo®▼ (radium-223 dichloride) | Efficacy

Explore efficacy of Xofigo®.

Xofigo Prescribing Information

PP-XOF-IE-0129-1, February 2026

Xofigo®▼(radium-223 dichloride) | Safety

Learn more about safety profile of Xofigo®.

Xofigo Prescribing Information

PP-XOF-IE-0130-1, February 2026

Xofigo®▼ (radium-223 dichloride) | Dosing & Administration

Discover dosing of Xofigo®.

Xofigo Prescribing Information

PP-XOF-IE-0131-1, February 2026

Abbreviations

ADT,

^{androgen deprivation therapy;}^AR,^{androgen receptor;}^EU,^{European Union;}^LHRH,^{Luteinising hormone releasing hormone;}^mCRPC,^{metastatic castration-resistant prostate cancer;}^mHSPC,^{metastatic hormone-sensitive prostate cancer;}^nmCRPC,^{non-metastatic castration-resistant prostate cancer.}

PP-XOF-IE-0128-1 | January 2026

^{▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.}

References

1
National Comprehensive Cancer Network. NCCN Guidelines® Version 4.2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Last Accessed December 2025).
2
Parker C, et al. Ann Oncol. 2015;26(suppl 5):v69-v77.
3
O’Sullivan JM, et al. Eur Urol Oncol. 2019; doi:10.1016/j.euo.2019.02.007.
4
Xofigo®(radium-223 dichloride): Summary of Product Characteristics.
5
Parker C, et al. N Engl J Med. 2013;369(3):213-223.
6
Shore ND. Urology. 2015;85(4):717-724.
7
Saad F, et al. Can Urol Assoc J. 2015;9(3-4):90-96.
8
Cookson MS, et al. J Urol. 2015;193(2):491-499.
9
Parker C, et al. Prostate Cancer Prostatic Dis. 2018;21(1):37-47.